Biomedical subjects

Zhi-lan Peng

Publications and source records attributed to Zhi-lan Peng.

22 records · Page 2Linked to original sources

PubMed2003

[Tissue microarray and in situ hybridization study on hypoxia inducible factor 1alpha mRNA expression in epithelial ovarian tumor].

OBJECTIVE: To study the expression and significance of hypoxia inducible factor 1alpha (HIF-1alpha) in epithelial ovarian tumors. METHODS: The expression of HIF-1alpha mRNA in 295 patients with epithelial ovarian tumor was analyzed retrospectively by high-throughput tissue microarray and in situ hybridization, which was compared with 13 normal ovarian tissue samples. RESULTS: The expression rates of HIF-1alpha mRNA were 0, 13.2%, 42.1% and 81.9% in normal ovarian tissue, benign, borderline and malignant ovarian tumors. Expression rate of HIF-1alpha mRNA in borderline and invasive tumor was significantly higher than those in normal ovarian tissue and benign tumor (P < 0.001). Statistical analysis revealed that the expression of HIF-1alpha mRNA was not related to FIGO stages or histological subtypes. Close negative relation was observed between the expression of HIF-1alpha mRNA and tumor histological differentiation (P < 0.001). CONCLUSION: The overexpression of HIF-1alpha may play an important role in oncogenesis of epithelial ovarian tumor. Tissue microarray is an efficient technique of molecular biology.

Adult↗

PubMed2003

[The effect of basic fibroblast growth factor in ovarian cancer growth and angiogenesis].

OBJECTIVE: To investigate whether basic fibroblast growth factor (bFGF) can induce the proliferation, invasion and angiogenesis of ovarian cancer or not. METHODS: Human ovarian cancer cell lines SKOV(3) 1 x 10(4)/ml were plated in 24-well dishes, bFGF at 5, 10,15 and 20 ng/ml was added and crystal violet staining was given daily for 8 days, cell numbers were counted by determining OD490. SKOV(3) cells were plated in the center of 50% extra cellular matrix gel, bFGF at 5 and 10 ng/ml was added and the migration distance of cells was measured daily. SKOV(3) 5 x 10(7)/ml were transplanted to BALB/c nude mice subcutaneous. One week later, bFGF, bFGF-MAb or 0.9% nature sodium was injected subcutaneously surrounding the tumor twice a week. Eight weeks later, the experiment ended and the volume of the tumors were measured. Intratumoral microvessel density (MVD) was measured by immunohistochemistry staining for factor VIII. RESULTS: bFGF at 0-10 ng/ml could stimulate the proliferation of SKOV(3) concentration dependently (P<0.05). On the fifth day, the cell proliferation in 10 ng/ml group was 121% above control. bFGF could stimulate the invasion of SKOV(3) concentration dependently (P<0.05). On the seventh day, the migration distance in 5 ng/ml group was 1.16 cm and 153% above control, and that in 10 ng/ml group was 1.86 cm and 245% above control. The average volume of transplanted tumors and MVD in bFGF group were 180% and 146% above control respectively those in bFGF-MAb group were 63.7% and 62.8% above control respectively. CONCLUSION: bFGF can stimulate proliferation, invasion and angiogenesis of ovarian cancer markedly; bFGF-MAb can inhibit the angiogenesis and growth of ovarian cancer.

Animals↗

PubMed2002

[Development of research for combined gene therapy and radiotherapy for cancer patients].

Cancer treatment is one of the most important fields in medical research. All strategies such as radiotherapy, chemotherapy, surgery, and gene-based therapy have their own advantage and disadvantages. Nowadays, a novel method which combined traditional therapy with gene therapy plays an important role in the field of cancer research. This review described the current state of combined therapies of gene-based and radiate radiotherapy. Meanwhile, we evaluated the prospect of this combined treatment.

Animals↗

PubMed2002

[Expression of lung resistant-related protein in ovarian cancer and its clinical significance].

BACKGROUND & OBJECTIVE: It was reported that there was negative correlation between the over-expression of lung resistant-related protein (LRP) and the sensitivity of cisplatin and cyclophosphamide. Also it was reported that the over-expression of LRP could predict the chemosensitivity and prognosis of ovarian cancer, and it was an independent index of remission and exist period. This study was designed to investigate the function of LRP in cisplatin resistance and the relationship with prognosis of ovarian cancer by combining with the chemosensitivity test. METHOD: 1. ATP bioluminescence assay was used to determine the drug sensitivity of 50 specimens of fresh epithelial ovarian cancer tissues. Patients' responses were obtained by accepted clinical assessment methods after three treatment courses. 2. Expression of LRP in 50 paraffin specimens of ovarian cancer was determined using immunohistochemistry. RESULTS: 1. The non-overexpression of LRP in ovarian cancer was 24%, and the overexpression of LRP was 76%. 2. The non-overexpression of LRP in the cisplatin-sensitive ovarian cancer was 10/12(75%), while in the cisplatin-resistance was 3/12(25%). There was no significantly different. 3. The over-expression of LRP was increased in advanced and low grade ovarian cancer, and there was significantly different. CONCLUSIONS: Expression of LRP is related to stages, grades, and chemosensitivity of ovarian cancer, and it could become an index of screening drug and judging the prognosis of patients.

Adult↗